



# *Arnica montana* Stimulates Extracellular Matrix Gene Expression in a Macrophage Cell Line Differentiated to Wound-Healing Phenotype

Marta Marzotto, Clara Bonafini, Debora Oliosio, Anna Baruzzi, Laura Bettinetti, Francesca Di Leva, Elisabetta Galbiati, Paolo Bellavite

Published: November 10, 2016 • <https://doi.org/10.1371/journal.pone.0166340>

## Abstract

*Arnica montana* (*Arnica m.*) is used for its purported anti-inflammatory and tissue healing action on injuries, but its cellular and molecular mechanisms are largely unknown. This work tested *Arnica m.* using an *in vitro* model of macrophages polarized towards a “wound-healing” phenotype. The macrophage cell line was cultured and differentiated with phorbol-myristate acetate and Interleukin-4, then exposed to centesimal (c) dilutions 2c, 3c, 5c, 9c, 15c or Control. Total RNA was isolated and cDNA libraries were sequenced on a NextSeq500 sequencer. Genes with significantly positive (up-regulated) or negative (down-regulated) differentially expressed genes (DEGs). A total of 20 DEGs were identified in *Arnica m.* 2c treated cells: 11 were up-regulated and 13 were down-regulated. The most significantly up-regulated function concerned epidermal growth factor-like region ( $p < 0.001$ ) and three genes of proteinaceous extracellular matrix: proteoglycan 2 (HSPG2), fibrillin 2 (FBN2), and fibronectin (FN1) ( $p < 0.01$ ). Protein assay confirmed increase of fibronectin production ( $p < 0.05$ ). The down-regulated transcripts derived from mitochondrial components of electron transport chain. The same groups of genes were also regulated by increasing concentrations (9c, 15c), although with a lower effect size. We further tested the healing potential of *Arnica m.* 2c on wound closure based on the motility of bone marrow-derived macrophages and found evidence of an effect in this system. The results of this work, taken together, provide new insights into the action of *Arnica m.* and identify extracellular matrix regulation by macrophages as a therapeutic target.

**Citation:** Marzotto M, Bonafini C, Oliosio D, Baruzzi A, Bettinetti L, Di Leva F, et al. (2016) *Arnica montana* Stimulates Extracellular Matrix Gene Expression in a Macrophage Cell Line Differentiated to Wound-Healing Phenotype. *PLoS ONE* 11(11): e0166340. <https://doi.org/10.1371/journal.pone.0166340>

**Editor:** Johnson Rajasingh, University of Kansas Medical Center, UNITED STATES

**Received:** February 5, 2016; **Accepted:** August 26, 2016; **Published:** November 10, 2016

**Copyright:** © 2016 Marzotto et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

and source are credited.

**Data Availability:** All relevant data are within the paper and its Supporting Information files. has been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO (GSE77381 and GSE77382 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77381> /[/geo/query/acc.cgi?acc=GSE77382](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77382))).

**Funding:** This work was supported by Boiron Laboratoires Lyon, [www.boiron.fr](http://www.boiron.fr). The funder analysis, interpretation, decision to publish, or writing the manuscript.

**Competing interests:** The authors have declared that no competing interests exist. This study was supported by Boiron Laboratoires Lyon with a research agreement in partnership with University of Verona. There are no products or marketed products to declare. This does not alter our adherence to all the PLOS ONE data and materials, as detailed online in the guide for authors.

## Introduction

*Arnica montana* L. (referred to here as *Arnica m.*) is one of the most popular medications in conventional medicine, employed in tincture, ointment, cream, gel, and tablet form. It is a herb native to the mountains of Europe and has been used to treat various pathological conditions, including pain, stiffness and swelling associated with trauma and clinical conditions (including contusions and sprains) and for symptomatic relief in osteoarthritis [1]. *Arnica m.* is generally applied only topically on the skin, while as a homeopathic formulation it is used orally—since it is not considered dangerous owing to the high dilution. The literature on *Arnica m.* in homeopathic preparations is rapidly increasing, but the knowledge of its action mechanism(s) remains limited [2].

The chemical composition of *Arnica m.* depends on the part of the plant that is used, principally the root. In general the most pharmacologically active compounds are sesquiterpene lactones, thymol derivatives, and polysaccharides and their glycoconjugates [6–8]. The ability of *Arnica m.* to inhibit activation of nuclear factor of activated T cells (NFAT) and pro-inflammatory cytokines IL-1 and TNF- $\alpha$  correlates with the qualitative content of sesquiterpene lactones [9].

There is some experimental evidence, in laboratory animals, of an anti-inflammatory action of an ethanolic extract [10] or at the 6<sup>th</sup> centesimal homeopathic dilution (6c) [11,12]. Additionally, *Arnica m.* reduces inducible NO synthase and cyclooxygenase-2 protein levels, a reduction in TNF- $\alpha$ , and prevents the activation of J774 murine macrophage cells without cytotoxicity *in vitro* [13]. Furthermore, oral treatment with *Arnica m.* in experimental animals (rats) against hepatic mitochondrial membrane permeabilization induced by the attack by reactive oxygen species [14].

Given the central role of macrophages in tissue repair and regeneration, we hypothesized that the primary targets of *Arnica m.* action is the macrophage, and accordingly decided to evaluate this plant's effect on a macrophage cell line, a widely used model for immune modulation [15,16]. This cell line is widely used in laboratory macrophage biochemistry and molecular biology. The advantage of a cell line resides essentially in the fact that all experiments are performed in the same conditions, avoiding the variations due to individual sensitivity of different subjects to doses of drugs—even with the highest *Arnica m.* 2c dilution, in assay medium the sesquiterpene lactone dose—we expected small effect sizes and so preferred to use a highly reproducible model. THP-1 cells are monocytes, but when treated with low doses of phorbol esters (PMA) they differentiate to cells with the functional features of tissue macrophages. On the basis of environmental cues and molecular signals, macrophages can polarize to either a pro-inflammatory type (M1) or to an anti-inflammatory or pro-reparatory type (M2) [17]. We used macrophages polarized by interleukin-4 (IL-4) treatment to a phenotype that takes on character

regulation, wound healing, and tissue remodelling [16,21].

In a preliminary study, we used RT-PCR analysis to investigate changes in the expression of a panel of genes involved in the immune response [22]. Among the tested genes, CXCL1 in particular exhibited the most substantial up-regulation. CXCL2, CXCL8, BMP2 and NFkB1 were slightly up-regulated, suggesting a positive influence of *Arnica m.* on cell recruitment and on angiogenesis. The most pronounced effects were noted in IL-4 polarized macrophages. Therefore, we decided to re-investigate the same cell extracts with the most high-throughput method (RNA-seq), designed to evaluate the whole transcriptome. We assessed RNA samples from a series of *Arnica m.* at the 2nd centesimal homeopathic dilution (*Arnica m. 2c*) compared with vehicle (Control). To identify all the potential genomic targets of the plant's regulating action, through bioinformatics analysis of genes (*Arnica m. 2c* vs Control) and using statistical methods correcting for false discovery rate. In addition, as *Arnica m.* is used at several doses in clinical settings [5], we also tested pooled samples of the experiments namely 3c, 5c, 9c and 15c. Lastly, to further investigate the potential therapeutic capacity of this plant, we tested Control solutions using an *in vitro* model of wound healing, in which macrophages migrate through a cell monolayer. A major advantage of this method is that it mimics, to some extent, the migration of cells in a wound, suitable for studies on the effects of cell-matrix and cell-cell interactions during wound healing.

## Materials and Methods

### Materials

The human monocytic leukaemia cell line THP-1 was purchased from DSMZ (Germany). Growth medium (DMEM with L-glutamine) and 20mM solution and DMEM with L-glutamine were purchased from Lonza (Belgium). Foetal bovine serum (FBS), 12-myristate 13-acetate (PMA), pure ethanol and ultra-pure water (W3500) were purchased from Sigma (USA). Human interleukin-4 (IL-4) was purchased from Macs-Miltenyi Biotec (Germany). Murine interleukin-4 (IL-4) was purchased from R&D Systems (UK). Cell proliferation reagent WST-1 was purchased by Roche Diagnostics GmbH (Germany). Ficol-Hypaque and Percoll were purchased from GE Healthcare Life Science (Uppsala, CA, USA).

### Test solutions

*Arnica m. 1c* was produced by Boiron Laboratoires (Lyon, France) according to the French Homeopathic Pharmacopoeia as a first centesimal dilution (*Arnica m. 1c*) of the hydroalcoholic extract (Mother Tincture, MT) in which the content of sesquiterpene lactones of the MT was determined by liquid chromatography and the pharmacopoeia standards was checked by thin layer chromatography. UV-visible absorption spectra were performed with a Jasco V-650 double-beam spectrophotometer using quartz cuvettes with 1cm path length. 30% v/v as the reference-blank sample. Nanoparticle content was determined by nanoparticle tracking analysis (NTA) using NanoSight LM10 (Malvern) instrument equipped with laser at 532nm and the NanoSight NTA 3.0 software. Particle size was measured by Zetasizer Nano (Malvern) using disposable capillary cells (Malvern).

*Arnica m. 1c* was used to prepare the second centesimal dilution (*Arnica m. 2c*) by adding 50µl of *Arnica m. 1c* to 5ml of ultra-pure water. Therefore, *2c* corresponds to  $10^{-4}$  of the MT. This solution was filtered with a 0.2µm filter and subjected to vigorous succussion with a Dyna-A mechanical shaker delivering 20 strokes/second with an amplitude of 10mm. A test solution was prepared using 30% ethanol/distilled water (same batch of the *Arnica m. 1c* dilution) and succussed as described for *Arnica m. 2c* sample. Final ethanol concentration in the test medicines were added as 10% of the final culture volume. This dose did not affect cell viability in our experiments.

Higher dilutions of *Arnica m.* were prepared as described previously [22]. Starting from a 1c solution, 5ml of 30% ethanol/distilled water solvent followed by filtering and succussion. Stock solutions of 30% ethanol/distilled water were wrapped in aluminium foil, stored at room temperature in the dark, and

preparation. The last centesimal dilution step was always performed immediately before each of the *Arnica m.* dilutions prepared in this way, those tested with the cells were: 2c, 3c, 5c, 9c, and 15c. All procedures for drug preparation and cell treatments were done in sterile conditions.

#### Cell cultures and treatments

The THP-1 cell line was cultured in RPMI 1640 medium, supplemented with FBS 10% and 2mM Ultraglutamine (Lonza), at 37°C in 5% CO<sub>2</sub> in a humidified incubator as described [22]. Briefly, on day 0 the cells were seeded at a density of 2.5×10<sup>5</sup> cells/mL in 24-well plates in 1ml medium with 2ml on day 2 all the cell cultures were supplemented with 20 ng/mL of PMA and on day 3 the cultures were supplemented with a concentration of 50 ng/mL for 24h. On day 4 the plates were washed twice with culture medium supplemented with 50 ng/mL IL-4 and incubated for 24h. Macrophages were exposed for 24h to the test solutions (1ml cell culture + 110µl test solutions). We performed a total of 5 complete separate experiments. For every treatment was performed in triplicate wells.

#### Bone marrow-derived macrophages

For the scratch test, bone marrow-derived macrophages (BMDM) were isolated from femurs of C57BL/6J mice as described by Suen et al. (1999) [24] and Baruzzi et al. [25]. Briefly, cells were isolated from bone marrow (Lonza) supplemented with 15% FBS, 10% L929-cell conditioned medium (LCM) as a source of IL-3, 100 U/ml penicillin, and 100 µg/ml streptomycin (BMDM complete medium), and cultured at 37°C/5% CO<sub>2</sub>. The non-adherent cells were removed, counted, plated on bacteriological (non tissue-culture-treated) plates at a concentration of 1×10<sup>5</sup>/ml, and cultured in BMDM complete medium.

#### Evaluation of cell viability

Cell viability was checked by the Cell proliferation reagent WST-1 assay. THP-1 cells were seeded in 96-well plates and differentiated with IL-4 as described above. After 24h of treatment with *Arnica m.* (v/v) pre-warmed WST-1 solution was added to the cells and the plate was incubated for 20 min. Absorbance at 450 nm was measured using a Victor3 multilabel reader (PerkinElmer, Shelton, CT, USA) at 45°C. Protein concentrations were quantified by Bradford assay according to the manufacturer's instructions.

#### RNA sequencing

Total RNA from cultured THP-1 cells was isolated using the RNeasy mini Kit (Qiagen). RNA quality was checked using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE). RNA samples were DNase treated using an RNA 6000 Nano Kit (Agilent, Wokingham, UK). The samples with RNA integrity number (RIN) > 7 were considered adequate for library preparation. RNA aliquots (2.5µg) were used to isolate poly(A) mRNA for the TruSeq RNA library using the TruSeq RNA Sample Prep Kit v2 (Illumina Inc., San Diego, CA). Before the generation of clusters, was checked with High Sensitivity DNA Kit (Agilent, Wokingham, UK). Library size was quantified by qPCR using the KAPA Library Quantification kit (Kapa Biosystems Inc., Woburn, MA).

Libraries were sequenced with a NextSeq500 sequencer (HighOutput flow cell with 75 sequencing cycles). The reads were aligned to the human reference genome (GRCh38) using the TopHat2 software. The expression value of known and novel genes was quantified as reads per kilobase of exon model plus transcript (RPKM) using the human working gene set (Ensembl release 80) as reference annotation. The effect of *Arnica m.* was calculated as Log<sub>2</sub> of the ratio between RPKM of each gene in *Arnica m.*-treated samples and Control (Co). Genes with Log<sub>2</sub> Fold Change values that were significantly positive (up-regulated) or negative (down-regulated) were defined as differentially expressed genes (DEGs).

Sequences of DEGs in the “protein coding” category were functionally annotated using Blast2G metabolic pathway in the Kyoto Encyclopedia of Genes and Genomes (KEGG) to the query seq classification and enrichment analysis were performed by DAVID Bioinformatics Resources 6.7 [27]. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus through GEO Series accession numbers GSE77381 and GSE77382 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77381>; <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77382>).

#### Protein quantification by ELISA

Matrix-related proteins (fibronectin, fibrillin, and heparan sulfate proteoglycan 2) were quantified in cells using ELISA assays: fibronectin human ELISA kit (Abcam), human Fibrillin-2 ELISA Kit and HSPG2 ELISA Kit (Cusabio), respectively.

#### In vitro wound-healing (scratch) assay

The capacity of macrophages to close an artificial “wound” was assessed using a culture model. BMDM monolayer was denuded of cells by scraping it with a pipette tip, after which the number of cells in the space was assessed microscopically [23]. Macrophages were cultured in 12-well plates in BMDM. On day 4, a portion of the cell cultures was supplemented with 20 ng/ml murine IL-4 while on day 5 the monolayers were wounded by transversely scratching the well with the tip of a 200 µl pipette. The detached cells were carefully aspirated and the wells washed with phosphate-buffered saline. The migration test was DMEM (Glutamax, pen-strep) with 2% FBS, either with or without 20 ng/ml IL-4. Solutions were added 24 h before wounding and maintained, during the migration time, at the same culture volume. Three sets of experiments were performed with triplicate wells for each condition. The field of the wound were acquired by means of contrast phase microscopy using an Olympus IX70 with 10x magnification to assess cell migration. The experiments were evaluated by examining micrographs and using a grid composed of 500 small frames to calculate the % of wounded area occupied by cells.

#### Statistics

RNA-seq analysis was performed separately on 5 experiments for *Arnica m.* 2c and Control solvent-treated cells. RNA samples from 5 experiments carried out with *Arnica m.* 2c and solvent were pooled and sequenced.

The evaluation of differential gene expression between the *Arnica m.*-treated and Control samples was performed using the DESeq2 package with a paired design [29]. Where indicated (Table 1), the False Discovery Rate (FDR) with the Benjamini and Hochberg method using an adjusted p-value. Comparisons were done by testing, for each gene and each experiment (N = 5), the null hypothesis exactly zero, i.e., that the gene was not at all affected by the treatment.

Effect	HGNC Nomenclature		RPKMIL-4 Control		RPKMIL-4 + Arnica m.		Log <sub>2</sub> Fold Change		Description	
	Symbol	ID	Mean	SE	Mean	SE	Mean	SE		
Up-regulated	CR1	2334	1.6	0.4	2.0	0.5	0.3	0.07	0.0205	Complement component (3b/4c) receptor 1
	LRP1	6602	19.4	2.0	23.6	2.0	0.29	0.05	< 0.0001	Low density lipoprotein receptor-related protein 1
	FN1	3776	436.3	30.8	509.5	23.4	0.27	0.05	0.0007	Fibronectin 1
	FN2	3654	3.0	0.2	3.6	0.1	0.27	0.09	0.0418	Fibronin 2
	HSPG2	5273	9.5	1.3	11.3	1.5	0.25	0.09	0.0332	Heparan sulfate proteoglycan 2
	KMT2D	7133	6.3	0.4	7.5	0.3	0.24	0.06	0.0037	Lysine (K)-specific methyltransferase 2D
	MACF1	13664	2.5	0.1	2.9	0.1	0.24	0.06	0.0379	Microtubule actin crosslinking factor 1
Down-regulated	COX3	7422	529.6	23.7	448.8	18.0	-0.24	0.05	0.0418	Mitochondrially encoded cytochrome c oxidase III
	ND2	7456	4766.7	289.3	3982.6	184.5	-0.25	0.04	0.0038	Mitochondrially encoded NADH dehydrogenase 2
	COX1	7419	1796.3	60.5	1506.3	46.7	-0.25	0.07	0.0418	Mitochondrially encoded cytochrome c oxidase I
	ND6	7462	85.2	4.4	70.2	1.8	-0.27	0.04	0.0018	Mitochondrially encoded NADH dehydrogenase 6
	ATP6	7414	404.9	15.1	334.1	11.3	-0.28	0.04	0.0008	Mitochondrially encoded ATP synthase 6
	ND5	7461	362.7	24.5	301.2	8.1	-0.28	0.06	0.002	Mitochondrially encoded NADH dehydrogenase 5
	ND1	7455	2061.5	112.5	1690.4	68.2	-0.3	0.061	0.0008	Mitochondrially encoded NADH dehydrogenase 1
	ND4	7459	819.0	41.2	658.1	16.6	-0.31	0.06	0.0006	Mitochondrially encoded NADH dehydrogenase 4
	MTFMR1L8	37185	43.6	4.1	36.3	1.4	-0.31	0.068	0.0176	MTFMR1-like 8
	CYTB	7427	35.1	2.2	28.1	1.5	-0.32	0.057	0.0001	Mitochondrially encoded cytochrome b
	CCDC88B	26757	5.4	0.5	4.3	0.3	-0.32	0.068	0.0078	Coiled-coil domain containing 88B
	ATP8	7415	1530.0	85.2	1218.2	38.6	-0.32	0.094	0.0135	Mitochondrially encoded ATP synthase 8
	ND4L	7460	102.6	7.4	79.5	2.0	-0.36	0.068	0.0006	Mitochondrially encoded NADH dehydrogenase 4L

**Table 1. Gene expression of IL-4 differentiated THP-1 macrophages, treated with Control solvent or *Arnica***  
<https://doi.org/10.1371/journal.pone.0166340.t001>

The statistical significance of the differences between expression profiles of gene groups (Up-regulated genesets) from cells treated with various *Arnica m.* dilutions (2c, 3c, 5c, 9c, 15c) was calculated followed by the Wilcoxon signed-rank test using the SPSS software, version 17 (SPSS Inc., Chi is a nonparametric test for multiple related samples (in this case, the multiple genes— 7 up-regulated cells treated with five *Arnica m.* dilutions and control solution) that checks the null hypothesis that terms of RPKM come from the same population. After verifying the significance of the Friedman signed-rank test for paired data to evaluate the differences between RPKM of genes after treatment and mean RPKM of Control-treated cells, and to check whether such differences were prevalently distributed between the two signs. The differences were accordingly ranked, and the positive and negative differences were summed and statistically compared using the specific Wilcoxon tables. The logic of this approach is the absence of treatment effects: if treatment has no effect the differences between gene expression profiles of treated and Control-treated samples should approach zero in all considered genes of the group (if the number of up- and down-regulated genes should be approximately equally significantly different). Log<sub>2</sub> Fold Changes were lower than or equal to ±0.05 (-0.05 < FC < 0.05) v


Comparison of protein release in *Arnica m.* 2c and Control samples was done with the Sigma P paired t-test, or the Wilcoxon Signed Rank Test when data were not normally distributed (as per normality test). Cell viability data were evaluated by ANOVA followed by Dunnett post-hoc test, t

Statistical evaluation of the scratch assay was done using the Friedman test. It is used to test for differences between groups (in this case the series of time points for the Treated and Control samples) when the dependent variable is not normally distributed. The null hypothesis is that the time series for two compared treatments (*Arnica m.* and Control) are

## Results

### Characterization of *Arnica m.*


The *Arnica m.* 1c used the starting material for this series of experiments was analysed by physicochemical methods. The UV-VIS absorption spectrum. This was characterized by a large UV peak around 220 and 280nm and 340nm. No substances absorbing at wavelength > 500 nm were detected in our pre



**Fig 1. Absorption spectrum of *Arnica m. 1c* used as starting material.**

<https://doi.org/10.1371/journal.pone.0166340.g001>

NTA analysis of the original *Arnica m. 1c* sample revealed the presence of a heterogeneous an nanoparticles ( $9.3 \pm 1.0$  particles/frame) corresponding to a concentration of  $1.83 \times 10^8 \pm 1.88 \times 10^8$  particles/ml. The NTA spectrum (Fig 2) showed a profile with about 6 peaks with a hydrodynamic diameter ranging from  $274.4 \pm 100.4$  nm. Zeta potential of these nanoparticles was  $-25.54 \pm 9.50$  mV ( $n = 12$  determinations).



**Fig 2. Nanoparticle spectrum of *Arnica m. 1c* used as starting material.**


The line is the average of 10 replicate measurements and vertical bars indicate SD.

<https://doi.org/10.1371/journal.pone.0166340.g002>

The amount of total sesquiterpene lactones in the original Mother Tincture was 36 mg/100ml. The molecular weight of *Arnica m.* sesquiterpene lactones is 340 g/mol [31], this amount is equivalent to  $1.05 \times 10^{-3}$  Mo of these active substances is  $1.05 \times 10^{-5}$  Mol/L in *Arnica m. 1c* and  $1.05 \times 10^{-7}$  Mol/L in *Arnica m. 1c* and  $1.05 \times 10^{-8}$  Mol/L in *Arnica m. 1c*.

#### Cell viability

The WST assay of cell viability (Fig 3) showed that the metabolic activity of macrophages, both differentiation, was slightly increased after 24h incubation with *Arnica m.* dilutions 2c and 3c, but vehicle was not statistically significant. Since the WST-1 assay depends on the level of NADH  $\mu$  shows that mitochondrial NADH-producing activity was not significantly impaired by *Arnica m.* It higher in IL-4 differentiated macrophages, irrespective of the presence of *Arnica m.*, suggesting basal metabolism of macrophages.



**Fig 3. Cell viability of macrophages.**

THP-1 macrophages in the resting state (diagonal bars) or after differentiation with IL-4 (cross-hatched bars) were incubated for 24 hours in the presence of *Arnica m.* at various dilutions or Control solvent. The histograms represent separate wells of a typical experiment. There are no significant differences between any *Arnica m.* dilutions (p>0.05).

<https://doi.org/10.1371/journal.pone.0166340.g003>

#### Changes in gene expression after *Arnica m.* treatment

The effects of *Arnica m.* treatment on the global gene expression of IL4-polarized THP-1 cells were analyzed by comparison with Control. The basic RNA-seq analysis was done in cells treated with the lowest dilution and highest dose that could be used since 1c contained a dose of ethanol incompatible with cell viability. The analysis was reproduced in 5 different biological replications. Approximately 25 million valid reads obtained from the sequencing were unambiguously annotated on 60434 gene transcripts. No arbitrary filtering of expression level was performed. Differential gene expression analysis was performed to identify significant target genes of *Arnica m.* statistically significant DEGs was thus obtained as shown in Table 1. The RPKM and Log<sub>2</sub> Fold Change values are shown in Table 1. The RPKM and Log<sub>2</sub> Fold Change values are shown in Table 1. The RPKM and Log<sub>2</sub> Fold Change values are shown in Table 1.

Mean RPKM is an indicator of the absolute amount of RNA in samples from cells treated with *Arnica m.* The most expressed gene was FN1 (fibronectin) and its RPKM values increased from 19.4 to 23.6. The second most expressed gene was LRP1 (from 19.4 to 23.6), and the third was HSPG2 (from 9.5 to 11.3). The analysis included 6 mitochondrially-coded NADH dehydrogenases which are subunits of Complex I, Cytochrome oxidases of Complex 4, and two ATP synthases of Complex V. In eukaryotes, the subunits of Complex I are encoded by the mitochondrial genome [33] and are normally highly expressed. *Arnica m.* treatment caused a slight but reproducible decrease of the expression of all the indicated genes (Table 1).

Mean fold changes, calculated as the average of the Log<sub>2</sub> Fold Change of the 5 replicates, ranged from 0.9 to 1.1.

up-regulation) to -0.36 (maximum down-regulation). The 7 up-regulated genes included low-density lipoprotein receptor-related protein 1 (LRP1), fibronectin 1 (FN1), lysine (K)-specific methyltransferase (KMT2D), complement C3, and heparan sulfate proteoglycan (perlecan, HSPG2), microtubule-actin crosslinking factor 1 (MACF1). The 13 down-regulated DEGs (13 genes) were mitochondrial genes coding for proteins of the mitochondrial complex I.

Functional gene enrichment analysis (Table 2) was performed by analysing international databases using the DAVID software. Among the genes stimulated by *Arnica m*, a statistically significant enrichment of HSPG2, FBN2, FN1 and Calcium ion binding motifs (LRP1, MACF1, FBN2) emerged (Fisher's exact test, p < 0.05). Most notably, a clearly up-regulated function concerned the proteinaceous extracellular matrix (FBN2, FN1 (p < 0.01)). The down-regulated genes converge into the common pathway of oxidative phosphorylation into the cell component gene ontology of mitochondrial complex I as expected (p < 0.001).

Geneset	Database	Function ID	Description	Fold Enrichment	P value	Genes
Up-regulated	INTERPRO	IPR013032	EGF-like region, conserved site	32.49	<0.001	LRP1, HSPG2, FBN2, FN1
	GOTERM_CC	GO:0005578	Proteinaceous extracellular matrix	17.12	<0.01	HSPG2, FBN2, FN1
	GOTERM_MF	GO:0005509	Calcium ion binding	7.06	<0.05	LRP1, MACF1, FBN2
Down-regulated	GOTERM_CC_FAT	GO:0005747	Mitochondrial respiratory chain complex I	161.44	<0.001	ND1, ND4L, ND4, ND5, ND2, ND6
	KEGG_PATHWAY	hsa00190	Oxidative phosphorylation	26.06	<0.001	ND1, ND4L, ND4, COX3, ND5, COX1, ND2, CYTB, ATP8, ND6, ATP6

**Table 2. Functional classification and gene enrichment analysis.**  
<https://doi.org/10.1371/journal.pone.0166340.t002>

**Protein release in supernatants**


To confirm the function of up-regulated genes, we measured the release of some relevant proteins into the supernatants. These, HSPG2 and fibrillin were detected only in traces, while fibronectin was identified in considerable amounts. The release of fibronectin protein was increased in IL-4 macrophages as compared with non-polarized cells and was increased in the presence of *Arnica m*.

		Normal Macrophages			IL-4-polarized Macrophages		
		<i>Arnica m</i> , 2c	Control	p	<i>Arnica m</i> , 2c	Control	p
HSPG2(Perlecan)	Mean	0.43	0.42	n.s.	0.35	0.31	n.s.
	SD	0.12	0.18		0.09	0.09	
Fibrillin	Mean	0.002	0.005	0.065	0.0004	0.0004	n.s.
	SD	0.001	0.003		0.0004	0.0004	
Fibronectin	Mean	1.62	1.41	0.063	22.91	17.49	0.031
	SD	0.65	0.51		22.21	15.50	

**Table 3. Proteins detected in supernatant of THP-1 macrophages cultivated 24 h in the presence and absence of *Arnica m*.**  
<https://doi.org/10.1371/journal.pone.0166340.t003>

PMA-differentiated THP-1 macrophages were polarized with IL-4 as described in Methods or maintained without IL-4 (Normal Macrophages), then both cultures were incubated for 24 h in the absence or presence of *Arnica m*. N = 6 complete experiments, assay in technical duplicates (HSPG2 and fibrillin) or triplicates (fibronectin) of 100 micrograms/million cells. Note that HSPG2 and fibrillin in some experiments were under the detection limit.


Fig 4 shows the amount of fibronectin detected in the supernatants in the 6 separate experiments. The effect of *Arnica m* was almost null in one experiment only, while in the other 5 it ranged from 13.9% to 100%.



**Fig 4. Fibronectin detected in supernatants of cell cultures in the absence and in the presence of *Arnica n***  
 Symbols indicate the fibronectin values of the same experiments in the two conditions of pol; percent effect as compared with Control of the same experiment.  
<https://doi.org/10.1371/journal.pone.0166340.g004>

**Testing higher *Arnica m.* dilutions**

We then investigated the changes induced by increasingly higher *Arnica m.* dilutions in the same significant alterations after treatment with 2c test solution (Table 1). These effects are reported in comparison with the mean of Controls and the RPKM of all samples are given in S1 Table, right (availability of sufficient volumes) and the high costs of RNA-seq, we could not separately assay five experiments at all the various dilutions. Therefore, to decrease experimental variability, we treated with the same *Arnica m.* dilution, using extracts from all the five experiments performed. variation possibly due to biological replicates, but meant we could not evaluate the standard error these reasons, Fig 5 (panels B-F) does not include the error bars for individual genes, but only for each group of genes (7 up-regulated in red, 13 down-regulated in blue). Since most of genes in belong to similar functional groups, calculating the mean of the various genes provided a first at major effects across different dilutions.



**Fig 5. Effects induced by increasing dilutions of *Arnica m.* on gene expression in THP-1 cells.** DEGs described in Table 1 were divided in the two groups as upregulated (red bars) and down-regulated genesets. Grey bars report the mean fold changes ± SE of the two genesets at each dilution Log<sub>2</sub> fold change values calculated from 5 experiments; Panels B-F *Arnica m.* 2c, 3c, 5c, 9c, pooled RNAs of 5 experiments. P values of Wilcoxon signed-rank test statistics are reported <https://doi.org/10.1371/journal.pone.0166340.g005>

The gray bars in Fig 5 show the means and standard errors of the *Arnica m.* effects for each gene down-regulated), with the p values of the differences between treatments and Control solvent. E the null hypothesis that treatment has no effect: in such a case the mean fold change values for approximate zero, and eventually (since some genes may be modified by chance), the mean of approach zero. Finally, if the null hypothesis is true, the number of up- and down- regulated genes or down-regulation—should be approximately the same.

Considering the *Arnica m.* 2c dilution (Fig 5, top two panels) we can see that the up-regulated genes responded in the pooled analysis (Panel B) roughly in the same direction as they did in the separate analysis; generally, looking at the red bars (which denote the genes previously found to be up-regulated) 7 were also up-regulated in this pooled analysis. Conversely, looking at the blue bars (denoting down-regulated) we see that all 13 of these genes are likewise down-regulated in this pooled analysis. The values of pooled samples were reliable also if done with a single RNA-seq assay. The difference

statistically only for each entire geneset (up-regulated or down-regulated groups of genes) by a test for paired data, testing whether the differences are mainly positive or negative, or evenly divided. The changes due to *Arnica m. 2c* were highly significant both in the mean of 5 experiments (Panel A) and in the standard deviation (Panel B). Absolute fold changes less than or equal to 0.05 were considered null.

For what concerns the higher dilutions, *Arnica m. 3c* (Panel C) similarly showed a prevailing stir up-regulated geneset: 6 genes out of a total of 7 (the exception was MACF1) were here also be genes of the previously down-regulated geneset were actually down-regulated also here (the exceptions were HSPG2 and CCDC88B). The changes of each geneset (grey bars) were approximately of the same magnitude as those induced by *Arnica m. 2c* and were statistically significant. *Arnica m. 5c* (Panel D) instead stimulated all genes of the up-regulated geneset and the prevailing inhibiting effect was also confirmed on the down-regulated geneset, with unchanged and of CCDC88B that showed an inversion of effect. *Arnica m. 9c* has a very faint effect on the up-regulated geneset, so that the global analysis was at limit of statistical significance threshold. On the downregulated geneset *Arnica m. 9c* had a faint but statistically significant effect, with the exception of CCDC88B. *Arnica m. 15c* slightly up-regulated 7 genes out of a total of 7, the strongest effect was on the downregulated geneset, *Arnica m. 15c* caused a slight but consistent downregulation of 10 genes, 10 and upregulated CCDC88B as seen with the lower dilutions. In summary, both upregulating and downregulating genes were maintained across the increasing dilutions, while for many considered genes a non-linear trend was observed.

#### Other candidate DEGs


The results presented thus far concern significant alterations of a series of genes identified through a global analysis under very stringent statistical tests—that is, after adjusting for FDR. By so doing, we minimized type-1 errors but also the probability of discovering true positive effects of *Arnica m.* on other candidate genes in the ECM. In point of fact, a large list of proteins with different roles are involved in the ECM change phases of wound healing and remodeling and includes various cell types. To explore the possible effects of *Arnica m.* on macrophages, we performed a further analysis which included a search for candidate genes without applying the correction ( $n = 476$ ). We then searched for the list of proteins interacting with the ECM organization (identifier R-HSA-1474244.1) and retrieved a list of 291 genes that represent the pathway organization. By matching these 291 genes with the 476 differentially expressed genes under *Arnica m.* treatment, we retrieved 22 genes, 13 of which were upregulated and 9 downregulated. The upregulated genes were HSPG2 as expected, plus fibrillin 1, nidogen, osteonectin, dystonin, MMP2 and ADAMTS2. metalloproteinases and the proteolytic enzyme calpain 3 resulted among the down-regulated DEGs. The genes already discovered with application of FDR and cited in Table 1) are reported in S2 Table, left panel. Other important proteins—e.g. periostin, osteopontin or tissue inhibitor metalloproteinases—does not appear in the list.

We also checked whether the same genes were affected by increasing drug dilutions (S2 Table, right panel). The trend was less regular than those observed with the group of genes described in Table 1 and Fig 5. Even if the same direction could be noted, most genes changed from up to down regulation or did not change at all. Only the genes ADAMTS2 and ITGAD responded to *Arnica m.* treatment in the same way (upregulated and downregulated respectively) in cells treated by all dilutions. Although this supplemental analysis should be considered as an indication of further genes involved, it suggests that in *Arnica m.* may affect ECM organization in a complex way.

In a previous study, which analysed a panel of inflammatory genes by RT-array, *Arnica m.* stimulated the expression of CCL2 (MCP-1), CXCL1, CXCL2, CXCL8, MRC1, NFKB1 and inhibited the expression of MMP1. This analysis, carried out on whole transcriptome with RNA-seq, confirmed the same trend of expression for those genes, albeit with values that do not attain statistical significance (data not shown). Of the only ones whose trend was not confirmed by RNA-seq were NFKB1 and TNFA, which did not change according to the present RNA-seq analysis. It should be noted that RNA-seq is a high-throughput method compared to gene-focused RT-PCR, a factor that may explain a partial discrepancy between the two cases: the interested genes have low expression values.

**Effectiveness on a wound healing model**

In order to investigate the possible functional implications of the observed molecular changes, cells treated with *Arnica m. 2c* comparing them with untreated cells. The scratch assay is an established method for measuring cell migration *in vitro* [23]. The test is based on the observation that, when a "scratch"—is created on a confluent cell monolayer, the cells on the edge of the newly created gap close the gap. To test *Arnica m.* in this system we used primary mouse bone marrow derived macrophages. This because in the previous experience of our department laboratory, and in our own test assays, we established stable monolayers and showed more consistent motility [25]. The left panels of Fig 6 show some of the assay.



**Fig 6. Wound closure effect of *Arnica m.***

Light microscope images of *in vitro* wound closure using a confluent monolayer of BMD macrophages show one representative experiment of cell migration into the created wound area in the absence (B and D) or presence (A and C) of *Arnica m. 2c*. Images A and B show the wound area immediately after the scratch, while images C and D show the wound area after 4.5 h. Pictures were acquired by means of contrast phase microscopy. The bar charts (E and F) report the gap width of the wound area before and after cell migration, expressed as a percentage of macrophage occupancy in the wound area in the absence (E) and in the presence (F) of 20 ng/ml IL-4. Gray bars: Control; yellow bars: *Arnica m. 2c*. Means±SE of three replicate wells of an experiment representative of the three performed. Statistical significance is indicated by Friedman tests (E: p=0.102, F: p=0.014). <https://doi.org/10.1371/journal.pone.0166340.g006>

Standardized scratches initially caused complete removal of the monolayers of BMD macrophages. A few hours later, the cells started to fill the gap sufficiently to allow the front line to be easily determined and quantified. In the presence of *Arnica m.* (Fig 6D) the filling of the gap was slightly faster than in the presence of IL-4. The same field was completely full of macrophages after 24 hours of incubation (98.8±0.7% occupancy with Control cells and 99.3±0.1% with *Arnica m.*, treated cells, n.s.) when only a part of the gap was filled (63.2±3.9% occupancy with Control cells and 62.3±7.0% with *Arnica m.* shown in figure). The bar charts on the right of Fig 6 represent the time-course of cell migration in the presence (F) of IL-4. *Arnica m. 2c* promoted a faster cell migration in both conditions but the difference be

and statistically significant only in the presence of IL-4 ( $p = 0.014$ ). The level of wound closure was higher than that obtained with the Control solvent.

## Discussion

Preparations from traditional medicinal plants are often used as alternative remedies aimed at repair [34,35]. However, according to the available literature in medical databases, the mechanisms of homeopathic remedies have yet to be fully understood. The application of whole plant extracts, formulations, may be beneficial because herbaceuticals can have multiple and pleiotropic targets to treat various pathological conditions such as bruises, swelling associated with trauma, pain, inflammation, and post-operative clinical conditions [3,5,37,38]. Investigations of its cellular and molecular targets and signaling pathways, but little is known about its possible action on the stages of tissue formation and repair. In this work, different dilutions of the whole plant extract in THP-1 human cells, differentiated into an IL-4 act on wound healing and tissue remodelling. RNA sequencing of whole transcriptome allowed the identification of genes whose expression was significantly altered following the treatment.

The physicochemical features of the *Arnica m.* used as a starting material to prepare further formulations through NTA, which provided a quantitative and morphological analysis of nanostructures in the extract, naturally during preparation of herbal extracts in liquid solution, and the presence of traces of silica has been observed to help nanoparticle nucleation [39]. Moreover, exosomes or lipidic plant debris have been suggested [40]. In this work, for the first time, *Arnica m.* preparations were found to exhibit polydispersed nanoparticles of 400 nm in size. These nanosized formations might represent a bioactive form of diluted herbal extract, as suggested [41–44], and this interesting hypothesis deserves further investigation.

The main and novel finding was the increased expression of several genes of tissue matrix proteins whose increase was confirmed also by protein assay in culture supernatants. This evidence suggests the role of this plant in wound-healing processes. In fact, most of the up-regulated genes which encode for extracellular matrix (ECM), and their enrichment as a functional group of genes is highly significant. These include collagens, proteoglycans/glycosaminoglycans, elastin, fibronectin, laminins, fibrillin, and several other components bind to each other as well as to cell adhesion receptors, forming a complex network. In tissue and epithelial cells bind to basement membrane and fibrillar components.

Fibronectin is a multi-domain protein with an essential role in the ECM since it binds to both cell and extracellular matrix fibres. Cell receptors for fibronectin transduce signals which regulate diverse functions, such as cell proliferation, whose regulation is vital during normal and pathological conditions [45,46]. This protein is vital for the maintenance of three-dimensional tissue architecture and for regulating cellular processes including adhesion, migration, and proliferation [47]. Fibronectin supports efficient platelet aggregation and pro-coagulant activity [48] and is involved in regulating the neovascularisation of granulation tissue during the resolution of tissue injury. Fibronectin is an important component of the early tendon repair process [49,50]. FN-1 gene is overexpressed in the late phase of inflammation, suggesting it has an important role in ECM deposition and tissue remodeling and in chronic inflammatory diseases [51]. Based on these considerations, we can formulate the hypothesis that the increase (20–30%) in the production of fibronectin induced by treatment with *Arnica m.* could improve wound healing and the migration of epithelial cells over the granulation tissue.

Other up-regulated genes included LRP1, HSPG2, and FBN2, which have an EGF-like domain. The significant association of these four genes into this functional group defined by enrichment analysis and the described changes of gene expression identify specific *Arnica m.* targets and can not be a random finding. EGF is an evolutionary conserved domain, which derives its name from the epidermal growth factor, which is involved in growth and tissue repair. Most occurrences of the EGF-like domain are found in the extracellular matrix proteins or in proteins known to be secreted, such as components of the extracellular matrix. The

is important in protein-protein interactions and the proteolytic release of this domain from membrane receptors involved in cell growth and survival [52]. The interaction between the EGF-like domain and calcium-dependent, a feature that is in keeping with the enrichment of calcium-binding group of

Low-density lipoprotein-receptor-related protein-1 (LRP1) is a receptor that mediates endocytosis and signaling. LRP-1 binds and internalizes numerous, structurally diverse ligands, delivering most of them to lysosomes for degradation [53]. LRP-1 also controls the plasma membrane proteome by regulating proteins in the secretory pathway [54]. Recently, its role as a regulator of inflammation has emerged to bind extracellular matrix proteins including fibronectin and thrombospondin [55] and to clear receptors of macrophage LRP1 to modulate endocytosis and protein degradation confers on it a role in repair after wound and inflammation—eg. adhesion and deadhesion processes, cell movements, clearance of proteases (e.g. MMP) that are generated in an inflammatory environment. In addition, LRP1 regulates modulating levels of connective tissue growth factor [57]. Finally, LRP-1 affects macrophage polarization and development of an anti-inflammatory M2 functional phenotype [58].

Heparan sulfate proteoglycan 2 (HSPG2, Perlecan) is a protein that in humans is encoded by this gene in basement membrane. HSPG2 is a key component of the cortical bone and serves as a link between the osteocyte cell body to the bone matrix. A reduction in perlecan secretion interferes with bone formation *in vivo* [59].

The protein encoded by KMT2D is a histone methyltransferase that methylates the Lys-4 position and regulates chromatin accessibility of adjacent genes and is associated with positive regulation of histone modifications induced by this protein, which are slight even after *Arnica m. 2c* treatment, may have been identified. In fact, many genes are expressed under the presence of this histone modification markers for M2 phenotype in IL-4 treated macrophages [60]. The gene MACF1 (microtubule associated factor 1) is likewise slightly but significantly overexpressed by *Arnica m. 2c* treatment. This protein has the ability to crosslink microtubules and F-actin networks, thereby directing microtubule organization. Directed cell migration, wound repair, and MACF1 has been observed to play a role in wound healing and epidermal migration required for rapid and efficient formation of a hyperproliferative epithelium in response to injury, on epidermal migration rather than proliferation [61].

The decreased expression of several mitochondrially-coded genes of respiratory chain is a puzzling phenomenon was accompanied by a decreased synthesis of related proteins, one would envisage a decrease in the respiratory chain and oxidative phosphorylation. Certainly, this expression change was not associated with cell damage, since cell viability was not changed upon *Arnica m.* treatment. Instead, the slight increase (statistically significant, and to be confirmed by further studies) could suggest an increased level of oxidative stress as a consequence of decreased consumption in the mitochondrial respiratory chain. Furthermore, since superoxide and free radicals in conditions of lack of oxygen and reperfusion [62], it is possible that a moderate increase in oxygen consumption could have a cytoprotective effect in conditions of lack of oxygen, such as those presumably encountered in wound tissue. This hypothesis is in agreement with the finding that a 30c dilution of *Arnica m.*, administered to mice, decreased oxygen consumption of isolated liver mitochondria and protected from oxidative damage [14]. The authors of that work interpreted this effect as a defence against oxidative stress. Furthermore, the whole extract of *Arnica m.* showed antioxidant activity and a cytoprotective effect against oxidative stress. Other reports an inhibitory action of *Arnica m.* on nitric oxide and TNF- $\alpha$  production by murine macrophages. Wound treatment with *Arnica m. 2c* increased cell motility, confirming that the drug does not inhibit the metabolism of the cell.

Among the down-regulated genes, the only non-mitochondrial gene was CCDC88B, coding for protein 88b, that is expressed in lymphocytes and myeloid cells and may have a role in regulating inflammation [64]. Interestingly, this gene showed an unusual behaviour in cells treated with different dilutions: decreased in samples from cells treated with low dilutions of *Arnica m.* (2c and 3c) while it increased in higher dilutions.

One of the major components of *Arnica m.* with an acknowledged biological activity is the sesquiterpene helenalin for its anti-inflammatory properties. In a lymphoid cellular model, helenalin was found to inhibit the NF- $\kappa$ B—a central mediator of human immune response—through the alkylation of p65 subunit binding to DNA [6]. However the cited studies did not evaluate the contribution of the whole plant concentration of  $10^{-5}$  Mol/L, much higher than that present in *Arnica m.* 2c used in this investigation; concentration in assay of  $1.05 \times 10^{-8}$  Mol/L. In this RNA-seq investigation, NFKB1 and RELA genes were upregulated by *Arnica m.* but, the reported effects of helenalin on NF- $\kappa$ B were due to the inhibition of proteasome activity at the transcription level. The role of the NF- $\kappa$ B system and other transduction factors in the regulation of the effects of *Arnica m.* remains to be further investigated.

Our findings provide a firm molecular explanation for previous experimental observations reported on inflammation and wound healing processes. In a randomized double-blind study conducted with a homeopathic dilution (4x) reduced wound irritation (redness, swelling and heat) after hallux valgus postoperative conditions in fewer days than did diclofenac [37]. An anti-inflammatory effect of *Arnica m.* carrageenan-induced foot oedema in rats has been reported by some authors [12] and a commercial *Arnica m.* plus other compounds at low dilutions (4x-6x) was effective for blood-induced experimental oedema as a topical gel improved the healing of surgically-induced wounds in Wistar rats, but significant effects of the drug was delivered together with microcurrent application [67]. A commercial homeopathic preparation (4<sup>th</sup> decimal, 4x) of *Arnica m.*, *Calendula* and *Hypericum* promoted fibroblast growth in a scratch assay [68]; the present work confirms this healing capacity of *Arnica m.* 2c (which corresponds approximately to 4x authors) also in macrophages, using a scratch-test model to evaluate cellular migratory events during the healing process. This same model has previously been proven a valuable tool for assessing the effect of the remedy, *Calendula officinalis* 3c, and of low-level laser therapy on human skin fibroblasts [69]. The effect of *Arnica m.* after treatment with *Arnica m.* can be due to many factors, including the augmented synthesis of extracellular matrix components, the ability to adhere to the surface of the well and to each other, also in virtue of the increased survival of cells.

At the present state of our knowledge, the mechanism of action of homeopathic medicines is explained without the help of a suitable working hypothesis. On the basis of all the evidence available, the hypothesis originally proposed by Khuda-Bukhsh [70] offers an acceptable logical explanation of the molecular biological action of diluted homeopathic remedies in living organisms—whether plants or animals. In microbiological models ultradiluted *Arsenicum* 30c or *Arnica m.* 30c modified the expression of genes involved in arsenite and UV irradiation injury, respectively [72–74]. Our studies [75,76] proved the extremelystimulated neurocyte gene network to centesimal dilutions (2c, 3c, 4c, 5c, 9c and 30c) of *Gelsemium s.* Oti. In non-neoplastic epithelial prostate cell lines treated with *Apis mellifica* (honey bee) homeopathic preparation, the expression of hundreds of genes after 24h incubation even with high dilutions 9c, 12c, 15c and 30c and their regulatory networks [78,79] may be the target of subtle messages by virtue of their flexibility in response to stimuli. These findings support the hypothesis that homeopathic remedies could turn some important genes into target genes. These gene actions to correct the gene expression that has gone wrong and produced the disorder or disease. A relevant target gene should be sensitive to similar stimuli and exert a pleiotropic transcriptional regulation of related functions.

The slight effect in this *in vitro* model does not mean that the modulating effect will also be small in vivo. Whereas conventional anti-inflammatory drugs are designed to suppress the underlying enzymatic activity (e.g. prostaglandins, cytokines) and act at considerably high doses, homeopathic treatment is directed to the pathological aspects and malfunctioning tissues, because the inflammatory process in itself is self-limiting and healing dynamics. In these conditions, even a 20–30% increase of macrophage activity in production of fibronectin may have a decisive positive outcome of tissue healing and repair. Moreover, given the multiplicity of its alkaloids, flavonoids, and sesquiterpene lactones [80], it is conceivable that the effect of *Arnica m.* is more complex and could involve modulation of different cells and further pathways. The field of connective tissue and cell matrix by natural and chemical compounds is open to further studies.

## Conclusions

The results of this work indicate that *Arnica m.* acts on macrophages by modulating a number of genes and cell motility. RNA-seq analysis allowed the identification of several genes which are particularly sensitive to dilutions of this plant extract. Molecular analysis of gene expression suggests that a primary action is the stimulation of tissue matrix synthesis. These findings provide new insights into wound-associated processes and point to macrophage fibronectin production as a potential therapeutic target of *Arnica m.* for the treatment of wounds.

## Supporting Information

**S1 Table. Expression values (RPKM) of Control and *Arnica m.*-treated cells and differential expression (Log<sub>2</sub> Fold Change) reported in Table 1.**

IL-4-differentiated THP-1 macrophages were treated with Control solvent or with *Arnica m.* 2c, 3c, 5c, 9c and 15 c. Samples from Control solvent and *Arnica m.* 2c were analysed by RNA-seq in each experiment. RNA samples from 5 experiments of cells treated with *Arnica m.* dilutions 2c, 3c, 5c, 9c and 15 c were pooled, analysed with RNA-seq and Fold Change calculated comparing their RPKM with the mean RPKM of Control values.

<https://doi.org/10.1371/journal.pone.0166340.s001>  
(XLSX)

**S2 Table. Expression values (RPKM) and differential expression (Log<sub>2</sub> Fold Change) of a series of extracellular matrix genes from the Reactome database as described in the text.**

The genes with FDR-adjusted p values > 0.05 and FDR unadjusted p values < 0.05 are here reported in Table 1. Samples from Control solvent and *Arnica m.* 2c were analysed in an experiment of five performed. RNA samples from 5 experiments of cells treated with *Arnica m.* dilutions 2c, 3c, 5c, 9c and 15 c were pooled, analysed with RNA-seq and Fold Change calculated comparing their RPKM with the mean RPKM of Control values.

<https://doi.org/10.1371/journal.pone.0166340.s002>  
(XLSX)

## Author Contributions

**Conceived and designed the experiments:** PB MM DO CB.

**Performed the experiments:** MM DO CB AB LB EG.

**Analyzed the data:** MM LB FDL.

**Contributed reagents/materials/analysis tools:** MM AB EG LB.

**Wrote the paper:** PB MM.

## References

1. Alonso D, Lazarus MC, Baumann L. Effects of topical arnica gel on post-laser treatment bruises. *Dermatol Surg*. 2003; 29(10):1164–1166. [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
2. Lawrence WT. Arnica. *Plast Reconstr Surg* 2003; 112: 1164–1166. [pmid:12973238](#)  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

3. Brinkhaus B, Wilkens JM, Ludtke R, Hunger J, Witt CM, Willich SN. Homeopathic arnica therapy in patients re randomised double-blind trials. *Complement Ther Med* 2006; 14: 237–246. pmid:17105693  
View Article • PubMed/NCBI • Google Scholar
4. Widrig R, Suter A, Saller R, Melzer J. Choosing between NSAID and Arnica for topical treatment of hand oste study. *Rheumatol Int* 2007; 27: 585–591. pmid:17318618  
View Article • PubMed/NCBI • Google Scholar
5. Iannitti T, Morales-Medina JC, Bellavite P, Rottigni V, Palmieri B. Effectiveness and Safety of Arnica montana Inflammation. *Am J Ther* 2016; 23: e184–e197. pmid:25171757  
View Article • PubMed/NCBI • Google Scholar
6. Lyss G, Schmidt TJ, Merfort I, Pahl HL. Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, se NF-kappaB. *Biol Chem* 1997; 378: 951–961. pmid:9348104  
View Article • PubMed/NCBI • Google Scholar
7. Douglas JA, Smallfield BM, Burgess EJ, Perry NB, Anderson RE, Douglas MH, Glennie VL. Sesquiterpene la method and the effects of flower maturity and simulated mechanical harvesting on quality and yield. *Planta M*  
View Article • PubMed/NCBI • Google Scholar
8. Sutovska M, Capek P, Kocmalova M, Pawlaczyk I, Zaczynska E, Czarny A et al. Characterization and pharma complex. *Int J Biol Macromol* 2014; 69: 214–221. pmid:24875316  
View Article • PubMed/NCBI • Google Scholar
9. Klaas CA, Wagner G, Laufer S, Sosa S, Della LR, Bomme U et al. Studies on the anti-inflammatory activity of flowers. *Planta Med* 2002; 68: 385–391. pmid:12058311  
View Article • PubMed/NCBI • Google Scholar
10. Sharma S, Arif M, Nirala RK, Gupta R, Thakur SC. Cumulative therapeutic effects of phytochemicals in Arnica induced arthritis: inhibition of both pro-inflammatory mediators and oxidative stress. *J Sci Food Agric* 2016; 96  
View Article • PubMed/NCBI • Google Scholar
11. Macedo SB, Ferreira LR, Perazzo FF, Carvalho JC. Anti-inflammatory activity of Arnica montana 6cH: preclini 84–87. pmid:15139092  
View Article • PubMed/NCBI • Google Scholar
12. Kawakami AP, Sato C, Cardoso TN, Bonamin LV. Inflammatory Process Modulation by Homeopathic Arnica n Variation. *Evid Based Complement Alternat Med* 2011; 2011: 917541. pmid:21318109  
View Article • PubMed/NCBI • Google Scholar
13. Verma N, Tripathi SK, Sahu D, Das HR, Das RH. Evaluation of inhibitory activities of plant extracts on produc mediators in J774 murine macrophages. *Mol Cell Biochem* 2010; 336: 127–135. pmid:19813079  
View Article • PubMed/NCBI • Google Scholar

- 14.** de Camargo RA, da Costa ED, Catisti R. Effect of the oral administration homeopathic *Arnica montana* on miI  
2013; 102: 49–53. pmid:23290879  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 15.** Qin L, Crews FT. NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activa  
Neuroinflammation 2012; 9: 5. pmid:22240163  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 16.** Chanput W, Mes JJ, Wichers HJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int I  
pmid:25130606  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 17.** Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23–35. pmid:12511873  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 18.** Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C et al. Genetic programs expressed in resting  
human macrophages: similarities and differences. Blood 2013; 121: e57–e69. pmid:23293084  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 19.** Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S et al. Macrophage activation and polarizatio  
guidelines. Immunity 2014; 41: 14–20. pmid:25035950  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 20.** Das A, Sinha M, Datta S, Abas M, Chaffee S, Sen CK et al. Monocyte and macrophage plasticity in tissue rep  
185: 2596–2606. pmid:26118749  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 21.** Chanput W, Mes JJ, Savelkoul HF, Wichers HJ. Characterization of polarized THP-1 macrophages and polari  
Food Funct 2012.  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 22.** Oliosio D, Marzotto M, Bonafini C, Brizzi M, Bellavite P (2016) *Arnica montana* effects on gene expression in a  
quantitative Real-Time PCR. Homeopathy 105: 131–147. pmid:27211321  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 23.** Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell  
329–333. pmid:17406593  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 24.** Suen PW, Ilic D, Cavegion E, Berton G, Damsky CH, Lowell CA. Impaired integrin-mediated signal transduc  
reduced motility in Hck/Fgr deficient macrophages. J Cell Sci 1999; 112 (Pt 22): 4067–4078.  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 25.** Baruzzi A, Remelli S, Lorenzetto E, Segal M, Chignola R, Berton G. Sos1 Regulates Macrophage Podosome

Capacity. *J Immunol* 2015; 195: 4900–4912. pmid:26447228

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 26.** Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptom and gene fusions. *Genome Biol* 2013; 14: R36. pmid:23618408

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 27.** Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bi 44–57. pmid:19131956

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 28.** Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array 207–210. pmid:11752295

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 29.** Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq. *BMC Bioinformatics* 2014; 15: 255. pmid:25516281

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 30.** Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple te (Methodological) 1995; 57: 289–300.

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 31.** Staneva J, Denkova P, Todorova M, Evstatieva L. Quantitative analysis of sesquiterpene lactones in extract o spectroscopy. *J Pharm Biomed Anal* 2011; 54: 94–99. pmid:20837387

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 32.** Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduc 127–152. pmid:16216776

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 33.** Hirst J. Mitochondrial complex I. *Annu Rev Biochem* 2013; 82: 551–575. pmid:23527692

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 34.** Budovsky A, Yarmolinsky L, Ben-Shabat S. Effect of medicinal plants on wound healing. *Wound Repair Rege*

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 35.** Maver T, Maver U, Stana KK, Smrke DM, Kreft S. A review of herbal medicines in wound healing. *Int J Derma*

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 36.** Mantle D, Gok MA, Lennard TW. Adverse and beneficial effects of plant extracts on skin and skin disorders. *A* 89–103. pmid:11482001

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 37.** Karow JH, Abt HP, Frohling M, Ackermann H. Efficacy of Arnica montana D4 for healing of wounds after Hall Altern Complement Med 2008; 14: 17–25. pmid:18199022  
View Article • PubMed/NCBI • Google Scholar
- 38.** Reddy KK, Grossman L, Rogers GS. Common complementary and alternative therapies with potential use in Am Acad Dermatol 2013; 68: e127–e135. pmid:21890235  
View Article • PubMed/NCBI • Google Scholar
- 39.** Bell IR, Schwartz GE. Enhancement of adaptive biological effects by nanotechnology preparation methods in 104: 123–138. pmid:25869977  
View Article • PubMed/NCBI • Google Scholar
- 40.** Mu J, Zhuang X, Wang Q, Jiang H, Deng ZB, Wang B et al. Interspecies communication between plant and r derived exosome-like nanoparticles. Mol Nutr Food Res 2014; 58: 1561–1573. pmid:24842810  
View Article • PubMed/NCBI • Google Scholar
- 41.** Chikramane PS, Suresh AK, Bellare JR, Kane SG. Extreme homeopathic dilutions retain starting materials: A 2010; 99: 231–242. pmid:20970092  
View Article • PubMed/NCBI • Google Scholar
- 42.** Bell IR, Schwartz GE. Adaptive network nanomedicine: an integrated model for homeopathic medicine. Front View Article • PubMed/NCBI • Google Scholar
- 43.** Bell IR, Ives JA, Jonas WB. Nonlinear effects of nanoparticles: biological variability from hormetic doses, sma interactions. Dose Response 2014; 12: 202–232. pmid:24910581  
View Article • PubMed/NCBI • Google Scholar
- 44.** Bhattacharyya SS, Mandal SK, Biswas R, Paul S, Pathak S, Boujedaini N et al. In vitro studies demonstrate a Gelsemium sempervirens. Exp Biol Med (Maywood) 2008; 233: 1591–1601.  
View Article • PubMed/NCBI • Google Scholar
- 45.** Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev 21 View Article • PubMed/NCBI • Google Scholar
- 46.** Meldolesi J. Pharmacology of the cell/matrix form of adhesion. Pharmacol Res 2016; 107: 430–436. pmid:265 View Article • PubMed/NCBI • Google Scholar
- 47.** To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. pmid:21923916  
View Article • PubMed/NCBI • Google Scholar
- 48.** Maurer E, Schaff M, Receveur N, Bourdon C, Mercier L, Nieswandt B et al. Fibrillar cellular fibronectin support procoagulant activity. Thromb Haemost 2015; 114: 1175–1188. pmid:26245230  
View Article • PubMed/NCBI • Google Scholar

49. Gelberman RH, Steinberg D, Amiel D, Akeson W. Fibroblast chemotaxis after tendon repair. *J Hand Surg Am* View Article • PubMed/NCBI • Google Scholar
50. Juneja SC, Schwarz EM, O'Keefe RJ, Awad HA. Cellular and molecular factors in flexor tendon repair and ad analysis. *Connect Tissue Res* 2013; 54: 218–226. pmid:23586515 View Article • PubMed/NCBI • Google Scholar
51. Gratchev A, Guillot P, Hakiy N, Politz O, Orfanos CE, Schledzewski K et al. Alternatively activated macrophag splice variants and the extracellular matrix protein beta1G-H3. *Scand J Immunol* 2001; 53: 386–392. pmid:112 View Article • PubMed/NCBI • Google Scholar
52. Fleck D, van Bebber F, Colombo A, Galante C, Schwenk BM, Rabe L et al. Dual cleavage of neuregulin 1 typ EGF-like domain and allows paracrine signaling. *J Neurosci* 2013; 33: 7856–7869. pmid:23637177 View Article • PubMed/NCBI • Google Scholar
53. Gaultier A, Hollister M, Reynolds I, Hsieh EH, Gonias SL. LRP1 regulates remodeling of the extracellular mati 22–30. pmid:19699300 View Article • PubMed/NCBI • Google Scholar
54. Gonias SL, Wu L, Salicioni AM. Low density lipoprotein receptor-related protein: regulation of the plasma mer 91: 1056–1064. pmid:15175790 View Article • PubMed/NCBI • Google Scholar
55. Gonias SL, Campana WM. LDL receptor-related protein-1: a regulator of inflammation in atherosclerosis, can *Pathol* 2014; 184: 18–27. pmid:24128688 View Article • PubMed/NCBI • Google Scholar
56. Yamamoto K, Troeberg L, Scilabra SD, Pelosi M, Murphy CL, Strickland DK et al. LRP-1-mediated endocytos ADAMTS-5 in articular cartilage. *FASEB J* 2013; 27: 511–521. pmid:23064555 View Article • PubMed/NCBI • Google Scholar
57. Strickland DK, Au DT, Cunfer P, Muratoglu SC. Low-density lipoprotein receptor-related protein-1: role in the *Thromb Vasc Biol* 2014; 34: 487–498. pmid:24504736 View Article • PubMed/NCBI • Google Scholar
58. May P. The low-density lipoprotein receptor-related protein 1 in inflammation. *Curr Opin Lipidol* 2013; 24: 134 View Article • PubMed/NCBI • Google Scholar
59. Wijeratne SS, Martinez JR, Grindel BJ, Frey EW, Li J, Wang L et al. Single molecule force measurements of  $\beta$  osteocyte pericellular matrix. *Matrix Biol* 2016; 50: 27–38. pmid:26546708 View Article • PubMed/NCBI • Google Scholar
60. Ishii M, Wen H, Corsa CA, Liu T, Coelho AL, Allen RM et al. Epigenetic regulation of the alternatively activate 3244–3254. pmid:19567879

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 61.** Wu X, Kodama A, Fuchs E. ACF7 regulates cytoskeletal-focal adhesion dynamics and migration and has ATF  
pmid:18854161  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 62.** Babot M, Birch A, Labarbuta P, Galkin A. Characterisation of the active/de-active transition of mitochondrial c  
1083–1092. pmid:24569053  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 63.** Craciunescu O, Constantin D, Gaspar A, Toma L, Utoiu E, Moldovan L. Evaluation of antioxidant and cytoprot  
Artemisia absinthium L. ethanolic extracts. Chem Cent J 2012; 6: 97. pmid:22958433  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 64.** Kennedy JM, Fodil N, Torre S, Bongfen SE, Olivier JF, Leung V et al. CCDC88B is a novel regulator of matur  
pathological inflammation. J Exp Med 2014; 211: 2519–2535. pmid:25403443  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 65.** Lussignoli S, Bertani S, Metelmann H, Bellavite P, Conforti A. Effect of Traumeel S, a homeopathic formulatio  
Complement Ther Med 1999; 7: 225–230. pmid:10709306  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 66.** Conforti A, Bellavite P, Bertani S, Chiarotti F, Menniti-Ippolito F, Raschetti R. Rat models of acute inflammatio  
effects of homeopathic remedies. BMC Complement Altern Med 2007; 7: 1. pmid:17233886  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 67.** Castro FC, Magre A, Cherpinski R, Zelante PM, Neves LM, Esquisatto MA et al. Effects of microcurrent applic  
Hypericum perforatum L. and Arnica montana L. on surgically induced wound healing in Wistar rats. Homeop  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 68.** Hostanska K, Rostock M, Melzer J, Baumgartner S, Saller R. A homeopathic remedy from arnica, marigold, S  
comfrey accelerates in vitro wound scratch closure of NIH 3T3 fibroblasts. BMC Complement Altern Med 201  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 69.** Bresler A, Hawkins D, Raziog R, Abrahamse H (2007) Effect of low level laser therapy and Calendula officina  
fibroblasts. Ind J Res Hom 2: 7–15.  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 70.** Khuda-Bukhsh A. Potentized homoeopathic drugs act through regulation of gene-expression: a hypothesis to  
in vitro. Compl Ther Med 1997; 5: 43–46.  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 71.** Bellavite P, Signorini A, Marzotto M, Moratti E, Bonafini C, Oliosio D. Cell sensitivity, non-linearity and inverse  
pmid:25869978

[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

- 72.** Das D, De A, Dutta S, Biswas R, Boujedaini N, Khuda-Bukhsh AR. Potentized homeopathic drug Arsenicum / biomarkers and gene expressions in *Saccharomyces cerevisiae* exposed to arsenate. *Zhong Xi Yi Jie He Xue* [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 73.** De A, Das D, Dutta S, Chakraborty D, Boujedaini N, Khuda-Bukhsh AR. Potentiated homeopathic drug Arsen reactive oxygen species generation and up-regulates expression of arsenic resistance gene in arsenite-expos *He Xue Bao* 2012; 10: 210–227. pmid:22313889 [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 74.** Das S, Saha SK, De A, Das D, Khuda-Bukhsh AR. Potential of the homeopathic remedy, Arnica Montana 30C exposed to ultraviolet irradiation through up-regulation of nucleotide excision repair genes. *Zhong Xi Yi Jie He* pmid:22409925 [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 75.** Marzotto M, Oliosio D, Brizzi M, Tononi P, Cristofolletti M, Bellavite P. Extreme sensitivity of gene expression in doses of *Gelsemium sempervirens*. *BMC Complement Altern Med* 2014; 14: 104. pmid:24642002 [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 76.** Oliosio D, Marzotto M, Moratti E, Brizzi M, Bellavite P. Effects of *Gelsemium sempervirens* L. on pathway-focu cells. *J Ethnopharmacol* 2014; 153: 535–539. pmid:24613275 [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 77.** Bigagli E, Luceri C, Dei A, Bernardini S, Dolara P. Effects of Extreme Dilutions of *Apis mellifica* Preparations c Dose Response. 2016 Jan 6;14(1):1559325815626685. [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 78.** Ramo P, Kesseli J, Yli-Harja O. Perturbation avalanches and criticality in gene regulatory networks. *J Theor B* [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 79.** Balleza E, varez-Buylla ER, Chaos A, Kauffman S, Shmulevich I, Aldana M. Critical dynamics in genetic regul kingdoms. *PLoS ONE* 2008; 3: e2456. pmid:18560561 [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
- 80.** Ganzera M, Egger C, Zidorn C, Stuppner H. Quantitative analysis of flavonoids and phenolic acids in Arnica r chromatography. *Anal Chim Acta* 2008; 614: 196–200. pmid:18420051 [View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)